子宫内膜异位症的治疗进展

www.yongyao.net　　2009-7-20 10:05:43　　来源：　　责任编辑：

分享到：

4 参考文献
[1] Suchy T, Stepan J.Extragenital endometriosis as a subject of interest for the surgeon[J].Rozhl- Chir, 2004, 83( 5) :239- 241.
[2] Cutner AS, Lazanakis MS, Saridogan E.Laparoscopic ovarian suspension to facilitate surgery for advanced endometriosis[J].Fertil Steril, 2004, 82( 3) :702- 704.
[3] K.Koga, Y.Takemura, Y.Osuga, et al.Recurrent of ovarian endometrioma after laparoscopic excision [J].Hum Reprod,2006, 21( 8) :2171.
[4] Sakamoto Y, Harada T, Horie S, et al.Tumor necrosis factoralpha- induced interleukin- 8 ( IL- 8) expression in endometriotic stromal cells probably through nuclear factor - kappa Bactivation:gonadotropin - releasing hormone agonist treatment reduced IL - 8 expression [J].J Clin Endocrinol Metab,2003, 88( 2) :730- 735.
[5] Matsuzaki S, Uehara S, Murakami T, et al.Quantitative analysis of estrogen receptor alpha and beta messenger ribonucleic acid levels in normal endometrium and ovarian endometriotic cysts using a real - time reverse transcriptionpolymerase chain reaction assay [J].Fertil Steril, 2000, 74( 4) :753- 759.
[6] Ishihara H, Kitawaki J, Kado N, et al.Gonadotropin- releasing hormone agonist and danazol normalize aromatase cytochrome P450 expression in eutopic endometrium from women with endometriosis, adenomyosis, or leiomyomas[J].Fertil Steril, 2003, 79( 3) :735- 742.
[7] Koray E, Linda R.Use of third generation gonadotropin - releasing hormone antagonists in in vitro fertilization - embryo transfer: a review [J].ObstetGynecolSurv, 2001, 56( 9) :576- 588.
[8] Basil TC, Helen BN.Gonadotropin- releasing hormone antagonists:inpact of IVF practice and potential non - assisted reproductive technology applications[J].CurrOpinObstetGynecol,2003, 15( 3) :259- 264.
[9] Jain J, Dutton C, Nicosia A, et al.Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo- Provera ( r) [J].Contraception, 2004, 70( 1) :11.
[10] Bulun SE, Fang Z, Imir G, et al.Aromatase and endometriosis[J].Semin Reprod Med, 2004, 22( 1) :45- 50.
[11] Amsterdam LL, Gentry W, Jobanputra S, et al.Anastrazole and oral contraceptives:anovel treatment for endometriosis[J]. Fertil Steril, 2005, 84( 2) :300- 304.
[12] Hefler LA, Grimm C, van Trotsenburg M, et al.Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis:a pilot study [J].Fertil Steril, 2005, 84( 4) :1033.
[13] Swisher DK, Tague RM, Seyler DE.Effects of the selective estrogen receptor modulator raloxifene on explanted uterine growth in rats[J].Drug Devel Res, 1995, 36( 1) :43- 45.
[14] Chwalisz K, Elger W, Stickler T, et al.The effects of 1 -month administration of asoprisnil ( J867) , a selective progesteronereceptor modulator, in healthy premenopausalwomen[J].Hum Reprod, 2005, 20( 4) :1090- 1099.
[15] DeManno D, Elger W, Garg R, et al.Asoprisnil ( J867) :a selective progesterone receptor modulator for gynecological therapy[J].Steroids, 2003, 68( 4) :1019- 1032.
[16] Nap AW, Griffioen AW, Dunselman GA, et al.Antiangiogenesis therapy for endometriosis [J].J Clin Endocrinol Metab,2004, 89( 3) :1089.
[17] Efstathiou JA, Sampson DA, Levine Z, et al.Nonsteroidal antiinflammatory drugs differentially suppress endometriosis ina murine model[J].Fertil Steril, 2005, 83( 1) :171.
[18] Soysal S, Soysal ME, Ozer S, et al.The effects of postsurgical administration of goserelin plus anastrozolecompared to goserelin alone in patients with severe endometriosis:a prospective randomized trial [J].HumReprod, 2004, 19( 1) :160.
[19] Dmowski WP, Pry M, Ding J.Cycle- specific and cumulative fecundity in patients with endometriosis who are undergoingcontrolled ovarian hyperstimulation- intrauterine insemination or in vitro fertiliz ation - embryo transfer [J].FertilSteril, 2002, 78( 4) :750- 756.